BeOne Medicines Ltd. American Depositary Shares —— 图表、价格与新闻 (NASDAQ:ONC)

展开完整图表

Financials

概览声明统计

每季度年度

Market Capitalization 34.3923 B
Employee 12 K
Founded 2010
CEO John Vincent OylerJohn Vincent Oyler
Website www.beonemedicines.com
Headquarter N/A
FIGI BBG00B6WF7T5
Industry Technology

总收入

净利润

每股基本收益（基本 EPS）

总债务

自由现金流

现金及现金等价物

34.39 B 市值

市盈率

1 599

市销率

83.86

BeOne Medicines Ltd - American Depositary Shares

BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment. Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market. BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024 the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025.